Adventitial Niches, Complement and Inflammation in Pulmonary Vascular Disease: Current Status and Future Directions

There is strong evidence supporting inflammatory and autoimmune processes in the pathogenesis of pulmonary arterial hypertension (PAH), although the initiating and disease-sustaining mechanisms remain unclear. Studies in arthritis, kidney disease, and cancer have demonstrated that dysregulation of the complement system can drive inflammation-mediated tissue injury. We have shown that activation of the complement cascade, particularly the alternative pathway, within the pulmonary vasculature is a key driver of proinflammatory responses in pulmonary hypertension (PH). Single-cell spatial transcriptomic analysis of PAH lungs further revealed complement-rich adventitial fibroblasts, granzyme K (GZMK)<sup>+</sup> CD8 T cells, and activated macrophages forming proinflammatory niches within the pulmonary artery adventitia in the different pulmonary vascular lesions in PAH. Our recent work highlights the role of both extracellular and intracellular complement activation in fibroblast-mediated pulmonary vascular inflammation. Specifically, activation of the alternative pathway within fibroblasts, through complement factors D (CFD) and B (CFB), promotes production of anaphylatoxins (C3a and C5a), cytokines, and complement-containing extracellular vesicles (EVs). These mediators drive macrophage and T-cell recruitment and activation, contributing to disease progression. Additionally, a fourth pathway of complement activation mediated by CD8<sup>+</sup> T cell-derived GZMK, which triggers extracellular complement cascades in fibroblasts and macrophages, has recently been identified. These findings support the hypotheses that local complement production by pulmonary artery adventitial fibroblasts, activated intracellularly by CFD and CFB and extracellularly by GZMK<sup>+</sup>, and its secretion in soluble form and within EVs promotes macrophage chemotaxis and activation. These complement-driven proinflammatory niches in PAH pulmonary arteries represent promising therapeutic targets in PH.

Authors

Institutions

Publication Details

Journal
Comprehensive physiology
Published
2026-03-26
DOI
https://doi.org/10.1002/cph4.70133
Primary Topic
Pulmonary Hypertension Research and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Adventitial Niches, Complement and Inflammation in Pulmonary Vascular Disease: Current Status and Future Directions

Kurt R. Stenmark, M. Li, Claudia Mickael, Yen‐Rei A. Yu et al.
Comprehensive physiology
Pulmonary Hypertension Research and Treatments
article

Adventitial Niches, Complement and Inflammation in Pulmonary Vascular Disease: Current Status and Future Directions

Kurt R. Stenmark, M. Li, Claudia Mickael, Yen‐Rei A. Yu, David Jones, Hui Zhang, Cheng‐Jun Hu, Ram Raj Prasad, Sushil Kumar, Rubin M. Tuder
article en

Abstract

There is strong evidence supporting inflammatory and autoimmune processes in the pathogenesis of pulmonary arterial hypertension (PAH), although the initiating and disease-sustaining mechanisms remain unclear. Studies in arthritis, kidney disease, and cancer have demonstrated that dysregulation of the complement system can drive inflammation-mediated tissue injury. We have shown that activation of the complement cascade, particularly the alternative pathway, within the pulmonary vasculature is a key driver of proinflammatory responses in pulmonary hypertension (PH). Single-cell spatial transcriptomic analysis of PAH lungs further revealed complement-rich adventitial fibroblasts, granzyme K (GZMK)<sup>+</sup> CD8 T cells, and activated macrophages forming proinflammatory niches within the pulmonary artery adventitia in the different pulmonary vascular lesions in PAH. Our recent work highlights the role of both extracellular and intracellular complement activation in fibroblast-mediated pulmonary vascular inflammation. Specifically, activation of the alternative pathway within fibroblasts, through complement factors D (CFD) and B (CFB), promotes production of anaphylatoxins (C3a and C5a), cytokines, and complement-containing extracellular vesicles (EVs). These mediators drive macrophage and T-cell recruitment and activation, contributing to disease progression. Additionally, a fourth pathway of complement activation mediated by CD8<sup>+</sup> T cell-derived GZMK, which triggers extracellular complement cascades in fibroblasts and macrophages, has recently been identified. These findings support the hypotheses that local complement production by pulmonary artery adventitial fibroblasts, activated intracellularly by CFD and CFB and extracellularly by GZMK<sup>+</sup>, and its secretion in soluble form and within EVs promotes macrophage chemotaxis and activation. These complement-driven proinflammatory niches in PAH pulmonary arteries represent promising therapeutic targets in PH.

Comprehensive physiologyVol. 16(2)
University of Colorado Anschutz Medical Campus (US)
Good health and well-being
Openalex Percentile: Top 6%
Pulmonary Hypertension Research and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.